PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of interfacehomepageaboutsubmitalertseditorial board
 
J R Soc Interface. Feb 6, 2013; 10(79): 20120536.
PMCID: PMC3565688
Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases
Akhilesh Kumar Shakya and Kutty Selva Nandakumar
Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
e-mail: nandakumar.kutty-selva/at/ki.se
Received July 6, 2012; Accepted November 1, 2012.
Polymers as an adjuvant are capable of enhancing the vaccine potential against various infectious diseases and also are being used to study the actual autoimmune responses using self-antigen(s) without involving any major immune deviation. Several natural polysaccharides and their derivatives originating from microbes and plants have been tested for their adjuvant potential. Similarly, numerous synthetic polymers including polyelectrolytes, polyesters, polyanhydrides, non-ionic block copolymers and external stimuli responsive polymers have demonstrated adjuvant capacity using different antigens. Adjuvant potential of these polymers mainly depends on their solubility, molecular weight, degree of branching and the conformation of polymeric backbone. These polymers have the ability not only to activate humoral but also cellular immune responses in the host. The depot effect, which involves slow release of antigen over a long duration of time, using different forms (particulate, solution and gel) of polymers, and enhances the co-stimulatory signals for optimal immune activation, is the underlying principle of their adjuvant properties. Possibly, polymers may also interact and activate various toll-like receptors and inflammasomes, thus involving several innate immune system players in the ensuing immune response. Biocompatibility, biodegradability, easy production and purification, and non-toxic properties of most of the polymers make them attractive candidates for substituting conventional adjuvants that have undesirable effects in the host.
Keywords: polymer, autoimmunity, vaccine, adjuvant, animal model
Over recent decades, material science research has been expanding exponentially to design and develop novel biomaterials for biomedical applications, and polymers have proved to be promising candidates. The easy and controllable synthesis of polymers in various formats with good mechanical properties, biocompatibility and biodegradability makes them more valuable in the biomedical field and in tissue engineering as scaffolds to grow mammalian cells for regeneration of damaged organs. Use of polymers in immunology as an adjuvant could be a useful substitute for conventional bacterial adjuvants. In immunology, an adjuvant is defined as the substance normally used with a weak antigen to enhance its immunogenic properties via activation of innate and adaptive immune responses. Adjuvants, such as polymers that are immunologically inert but capable of inducing an immune response when given with an antigen, have several advantages. Generally, they act as depot carriers through slow release of the antigen, thereby modulating the ensuing immune responses. Polymers mixed with an antigen can follow different signalling pathways. For example, the polymer–antigen can be phagocytosed and processed through proteasomes, activation of inflammasome pathway via secretion of IL-1β cytokine, ligand for toll-like receptor(s) or directly interact with B cells. Alternatively, processed antigens can be presented by antigen-presenting cells via major histocompatibility complex (MHC) molecules to naive T cells, which in turn can become activated and release various cytokines leading to enhanced T and B cell interactions. The activated B cells in turn can undergo differentiation into antibody-secreting plasma cells [1,2] (figure 1), and the antibodies thus produced can activate the downstream events of the effector phase of an immune response involving various chemokines, cytokines, proteases and effector cell populations such as neutrophils, macrophages, osteoclasts, mast cells and eosinophils [3].
Figure 1.
Figure 1.
Schematic diagram of possible mode of action of polymeric adjuvants. TLR, toll-like receptor; TCR, T cell receptor; IL, interleukin.
Conventionally used adjuvants are alum compounds [4], Freund's adjuvants (complete Freund's adjuvant, CFA and incomplete Freund adjuvant, IFA) [5], diphosphoryl lipid A [6], muramyldipeptide, monocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor [7] and oligodeoxynucleotides containing CpG motifs [8]. Among them, Freund's adjuvants are frequently used and well characterized, involving slow release of injected antigen and the pathogen-associated molecular patterns of the mycobacteria present in this adjuvant interacts with the pathogen recognition receptors such as toll-like receptors (TLRs), leading to the activation and proliferation of T cells [9]. The mycobacterium component of CFA specifically activates the Th1 pathway, resulting in the initiation of the delayed-type hypersensitivity reaction against the injected antigen [10]. Moreover, some systemic effects were also observed in the blood system characterized by proliferation of Mac-11+ immature myeloid cells. While, IFA does not have this mycobacterium content, it activates the Th2 pathway with a strong bias towards the humoral immune response [11]. However, the paraffin oil present in Freund's adjuvant has been shown to be non-degradable and cause toxicity problems [12]. In recent years, polymers have proved to be promising candidates to replace such conventional adjuvants with their biocompatible and biodegradable properties. These polymers, together with an antigen, can activate the immune response effectively and have thus been used as an adjuvant in vaccination strategies and in the induction of autoimmune responses.
Vaccination is the most effective way to control and prevent diseases. But multiple doses of conventional vaccines for the activation of the desired immune responses are very difficult and challenging, especially in developing countries. Interestingly, polymers in vaccine formulations could improve the delivery of antigens and thus reduce the booster doses of vaccines required for the activation of an appropriate immune response. For many decades, various biodegradable natural and synthetic polymers have been used for antigen delivery for the controlled release of vaccines over longer periods of time and as an adjuvant for enhancing immunogenicity of weak vaccines (table 1). In this review, we will discuss the application of polymers as adjuvants in vaccination.
Table 1.
Table 1.
Polymeric adjuvants used in vaccination.
2.1. Natural polymers
Numerous polysaccharides originated from plant and microbes have been tested for their adjuvant potential in vaccination. In this scenario, various derivatives of dextran have shown to have immunological properties. The sulphate-derivatized form of dextran sulphate was shown to have anti-inflammatory properties in vivo and it was used in the induction of inflammatory colitis in mice [13]. Another derivative, diethylaminoethyl dextran (DEAED), is polycationic in nature and has been used as a vaccine adjuvant. DEAED, together with Venezuelan equine encephalomyelitis virus antigen, induced primary antibody responses after vaccination of rhesus monkeys [14]. In another study, adjuvant properties of DEAED were proved in mice immunized with whole-cell cholera vaccine [46]. Another derivative of dextran, acetylated dextran, in the form of microparticles was proven to be an activator of toll-like receptor pathways and to induce inflammatory cytokines [15].
As an adjuvant, lentinan, another polysaccharide composed of β-1,3-glucohexaose monomer units with β-1,6 branching has been demonstrated in a vaccination study. Lentinan activated macrophages with an increasing respiratory burst activity and IL-6 production after lethal influenza virus infection [47]. It also enhanced antigen presentation through a dendritic cell vaccine procedure, leading to the activation of T and natural killer cell populations with a concomitant production of cytokines by splenocytes [48]. The sulphated derivative of lentinan was proven to be a powerful adjuvant in chickens immunized with Newcastle disease vaccine with an increased serum antibody titre and proliferation of lymphocytes [17]. Moreover, lentinan suppresses tumouricidal activity of macrophages non-specifically unlike other adjuvants such as lipopolysaccharide (LPS) [49].
Inulin, another polysaccharide, is a linear chain polymer linked through a β(2–1) glycosidic bond. Adjuvancity of inulin was linked to the activation of the complement cascades [50]. Structurally, inulin occurred in various isoforms α, β, γ and δ. Out of these, γ inulin was proven to be a powerful adjuvant in immune activation [18]. More recently, δ inulin has been characterized as a more potent adjuvant than the γ isoform, enhancing both humoral and cellular immune responses when administrated together with an antigen [51]. The T cell memory immune response was also strong as evidenced by a higher cellular proliferation rate. In addition, enhanced production of antigen-specific antibodies was also noticed [52]. Furthermore, δ inulin has been effective with Japanese encephalitis [13] and HIV vaccine antigens [19]. Its mechanism of action is mainly through interactions with APCs, including monocytes, macrophages and dendritic cells. However, unlike other adjuvants, it is unable to activate the pro-inflammatory NF-κB pathway. But a positive aspect of inulin adjuvants is that like many other carbohydrate compounds, they are well tolerated by the body and cause minimal reactogenicity [53].
In this direction, mannan polysaccharide is also known as a vaccine adjuvant that mainly binds to mannose receptors and leads to the activation of the complement pathway with enhanced phagocytosis of the antigen [54,55]. In addition, it also operates via the inflammasome pathway through secretion of IL1β and as a ligand for TLR4 [56]. The reduced form of mannan (mannose) is known for the activation of the Th2 pathway when administrated with an antigen, while oxidized mannan in known to activate the Th1 pathway [57]. Mannan coupled with a recombinant protein antigen was shown to enhance higher production of specific IgGs compared with cholera toxin [20]. The acetylated derivative of mannan (Acemannan) has also shown anti-viral and anti-tumour activities. It has the capacity to induce maturation of DCs through upregulation of MHC class II molecules and production of IL-12 [21]. Interestingly, mannan has been shown to induce not only transient arthritis in naive BALB/c mice but also Th17-mediated chronic arthritis in ZAP-70 mutated (SKG) mice via activation of innate immunity through toll-like receptors and dectin-1 [58]. However, C5a receptor (C5aR) deficiency in SKG mice inhibited the differentiation/expansion of Th17 cells after mannan or β-glucan treatment, and consequently suppressed the development of arthritis [59]. Recently, we have also found in naive mice that mannan can induce inflammation that is dependent on MHC class II but not on complement factor 5 (Khmaladze et al. 2012, unpublished data).
Subsequently, another natural polymer, chitosan, was shown to exhibit a range of immunological properties, including macrophage activation, cytokine production and enhanced antibody synthesis when co-delivered with an antigen. Similar to mannan, chitosan interacts with dectin-1 and toll-like receptors. Mostly, chitosan has been used for antigen delivery in the form of particles [6062]. Recently, inactivated influenza virus vaccine entrapped in chitosan particles was found to increase the antibody titre two- to 10-fold more after intramuscular immunization in mice than the controls [23]. In other study, chitosan polymer has been used as an adjuvant in the form of particles for delivery of HBsAg antigen with an enhancement of immunogenicity ninefold more compared with naive mice [22]. Owing to the mucoadhesive property of chitosan, the N-trimethylchloride derivative of chitosan was used to demonstrate enhanced immunogenicity and protective efficiency through increased absorption of proteins at the mucosal surfaces by opening tight junctions [24]. In few studies, chitosan particles have been used in combination with alginate for delivery of HBsAg with CpG adjuvant via the intranasal route, which induced significant antibody responses [63]. Furthermore, chitosan as an adjuvant enhanced protection against Helicobacter pylori through induction of Th2 responses [64]. Similarly, trimethyl and mono-N-carboxymethyl chitosan-based nanoparticles encapsulated with tetanus toxoid antigen enhanced both mucosal and systemic immune responses in response to vaccination via the nasal route [65]. To prove this concept, Verheul et al. [66] fabricated trimethylchitosan particles with hyaluronic acid and found improved adjuvant potential compared with trimethylchitosan particles alone for nasal and intradermal vaccinations.
Poly-γ-glutamic acid (PGA) is another polypeptide that is composed of gamma-linked glutamic acid units with an alpha carboxylate side group, produced by Bacillus bacteria. PGA with l-phenylalanine ethyl ester has shown immunologic activity in the form of particulates. Ovalbumin-entrapped γ-PGA nanoparticles have activated human monocyte-derived dendritic cells and enhanced the production of inflammatory cytokines and chemokines [25]. Moreover, it was involved in the upregulation of co-stimulatory molecules, leading to better T-cell priming. In another study, γ-PGA particles induced innate immune cells in vitro and produced antigen-specific immune responses through TLR4 and MyD88 signalling pathways [67]. Recently, γ-PGA and benzalkonium-chloride-based anionic complexes were successfully encapsulated with ovalbumin antigen that were shown to be efficiently taken by dendritic cell line, DC 2.4. Subcutaneous administration of these complexes induced antibodies with activation of both Th1 and Th2 pathways [68].
2.2. Synthetic polymers
Synthetic polymers as an adjuvant have several benefits over conventional metal-based adjuvants such as alum compounds. Polymers in the micro/nano-size range can be directly internalized via the lymphatic system and retained for a longer period of time, which helps to maintain a significant level of immune response and thus reduce multiple doses of antigen required for activation of the immune system. They are biocompatible, easy to degrade and non-toxic to animals, unlike alum compounds.
2.2.1. Multiphase emulsions
Among the various adjuvants available for vaccination, adjuvants based on emulsion such as Freund's adjuvant, montanide ISA 51 have the advantage of being easy to manufacture at low cost. Generally, these adjuvants are defined as water-in-oil emulsion with dispersed antigen [26]. However, preparation time, injection difficulties and localized toxicities at the injection site are considerable problems with these emulsions [59,69]. To improve injectiblity, a new method consisting of re-dispersion of these emulsions in an aqueous phase using the hydrophilic emulsifier Tween-80 (polyoxyethylene sorbitan monooleate) has been demonstrated [70]. The adjuvancity of Tween-80 proved more immunogenic than controls; however, Tween-80 has been restricted in use owing to its lipophilic toxicity and extra reactivity problems [71,72]. To reduce the toxicity problems, a synthetic block polymer with low molecular weight has been suggested as a good alternative to surfactants [73]. For example, TiterMax is squalene-based water-in-oil emulsion containing polyoxyethylene–polyoxypropylene–polyoxyethylene (POE–POP–POE) polymer [74]. However, mild toxicity has also been reported with the use of the TiterMax adjuvant owing to its poor biodegradation properties [75]. To further improve this adjuvant, recently Huang et al. have proposed multiphase emulsion based on the polymeric emulsifiers poly(ethylene glycol)-blockpolylactide (PEG-b-PLA), poly(ethylene glycol)-block-poly(epsilon-caprolactone) (PEG-b-PCL) and poly(ethylene glycol)-block-poly(lactide-co-epsilon-caprolactone) (PEG-b-PLACL) in the antigen phase of oily ISA51-adjuvant-based vaccines. Good biodegradability and biocompatibility of these polymers makes them promising candidates for vaccines [76].
2.2.2. Polyphosphazenes
Polyphosphazenes are one of most frequently used polymers as an adjuvant, which consists of alternate nitrogen and phosphorus elements in the backbone with organic side groups. Polyphosphazene-based polymers generally form stable complexes with an antigen and thus produce more potent adjuvant preparations [77,78]. Their synthetic flexibility and susceptibility towards hydrolysis produces a promising matrix for adjuvants in vaccine formulations. Among polyphosphazene, poly(di(sodium carboxylatophenoxy)phosphazene, PCPP) was demonstrated for its adjuvant activity with influenza and other retrovirus-based vaccines [27,28]. Recently, PCPP has been injected with influenza virus X31 antigen subcutaneously and strong B and T cell responses were observed [79]. In another study, the adjuvant effect of PCPP was studied in combination with CpG oligodinucleotides via the subcutaneous route [80]. Recently, Shim and co-workers [81] demonstrated the adjuvant potential of PCPP via the mucosal route. Interestingly, PCPP has a film-forming nature and is thus able to encapsulate the antigen efficiently even under mild conditions. It is a water-soluble molecule, which can be easily formulated with proteins and has the capacity to dissolve in a highly hydrated environment. Owing to this dual functionality of PCPP (as an adjuvant and film-forming nature), it is one of the most promising materials available for use in vaccine delivery [82].
2.2.3. Polyelectrolytes
Very recently, polyelectrolyte multilayer capsules (PMLC) have been demonstrated as a carrier for antigen delivery [8385]. PMLC can easily be self-assembled under aqueous conditions without the aid of any other chemicals, which may denature the antigen. Usually, PMLC are fabricated in three steps: encapsulation of antigen in porous microtemplates [86] followed by layer-by-layer coating of polymers [87] and removal of microtemplates through decomposition into low-molecular-weight components. These porous multilayer capsules rapidly rupture during cellular uptake and permit rapid intracellular release of the encapsulated antigen. De Geest et al. [29] have fabricated PMLC composed of dextran sulphate and poly-l-arginine encapsulated antigen, which was rapidly phagocytozed by dendritic cells, resulting in better antigen presentation to CD4+ and CD8+ cells. Subsequently, these capsules were demonstrated as carriers for an antigen in pulmonary vaccination. PMLC are efficiently uptaken by alveolar macrophages, followed by initiation of Th17 immune responses, which is considered a central part in mucosal immune responses. Furthermore, PMLC-based immunization was also shown to provide protective immunity against B16 melanoma and influenza infection. High doses of PMLC activate the NALP inflammasome pathway.
Similarly, a cationic lipopolymer, liposome–polyethylene glycol–polyethyleneimine complex (LPPC), was also evaluated for adjuvant and immunomodulation properties. LPPC strongly adsorbs the antigens over the surface and enhances the immune responses. It was found that this polymer–antigen complex activates immune responses through enhanced uptake and presentation of antigens, cell surface receptor expression and release of pro-inflammatory cytokines. When, LPPC was given with LPS or CpG oligodeoxynucleotides, a strong level of IgA antibody responses was observed [30].
Water-soluble, non-toxic and synthetic polyelectrolytes were found to be efficient immunomodulators [88]. A more prominent increase in antibody responses was achieved by complexing an outer membrane protein of Salmonella, porin, with the heteropolymer, polyoxydonium [89]. Similarly, Salmonella O and H antigens complexed with polyelectrolytes have been shown to induce several-fold higher antibody responses against respective antigens [90].
2.2.4. Polyanhydrides
Polyanhydrides are a novel class of biodegradable polymers that have been extensively used in protein/antigen delivery in vaccinations [91,92]. In recent years, this polymer has been approved by the FDA for human use owing to its tissue compatibility and controlled biodegradation properties [93]. Degradation of this polymer occurs through surface erosion mechanisms, resulting in controlled release of antigens. Normally, degradation can be extended up to one month depending on the polymer chemistry [74,94]. Furthermore, controlled release of antigen activates the immune system requiring only a single injection, which potentially improves patient compliance [95]. Intrinsic adjuvant activity of polyanhydrides has been reported that was independent of the type of antigen delivered. Recently, Torres et al. [96] reported adjuvant activity of various polyanhydrides, including sebacic anhydride, 1,6-bis(p-carboxyphenoxy)hexane (CPH) and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG). A specific combination of CPH and CPTEG copolymer microparticles has been used as vaccine adjuvants and carriers for antigen. These particles were efficiently phagocytosed by APCs and localized in phagolysosomes. Expression of surface markers CD86, CD40 and MHC class II on dendritic cells was significantly increased after phagocytosis of microparticles. Moreover, the presence of polyanhydride particles induced specific proliferation of CD4+ and CD8+ T-cells. Recently, molecular design of amphiphilic polyanhydride nanoparticles has been proposed for the activation of APCs mimicking pathogens [97]. The dose–response effect of poly(methyl vinyl ether-co-maleic anhydride) nanoparticles was studied in the stimulation of TLRs. These particles were also involved in the activation of the complement pathway [98].
2.2.5. Non-ionic block copolymers
Non-ionic block copolymers containing polyethylene (POE) and polypropylene (POP) blocks are known as poloxamers/pluronics [99]. Experiments have proven the capability of low molecular weight pluronic polymers (3 kDa) with 90 per cent POP and 10 per cent POE in the activation of macrophages. Intraperitoneal injection of these copolymers in mice induced high-level expression of MHC class II molecules, which is a direct indication of macrophage activation [100,101]. Although the exact mechanism of action of the block copolymers has not been delineated, these polymers are known to work through the activation of the alternative pathway of the complement system [102]. It is of interest to note that certain complement proteins are also involved in the activation of macrophages [74]. These copolymers are also known for the stabilization interactions of protein antigens at the interface of oil- and water-based emulsions [103]. One of the major limitations of these copolymers is their poor solubility in aqueous formulations owing to their low molecular weight (2000–5000 Da), making it necessary to use them in oil-based emulsions only. To improve the solubility, Todd et al. [33] synthesized a larger molecular weight block copolymer CRL1005 (9000 Da), which was compatible in aqueous formulations. The CRL1005 polymeric adjuvant has a higher POP content, around 95 per cent compared with 80–90% POP in small-molecular-weight copolymers. These large polymers are soluble in water at 18°C but form aggregates at body temperature.
Recently, an interesting form of block copolymers known as polymersomes have been demonstrated in vaccine delivery for the activation of immune responses [104,105]. Generally, polymersomes are composed of amphiphilic block copolymers, which after self-assembly form polymeric shells. Polymersomes composed of POE glycol-polybutadiene block copolymer nanoparticles functionalized with Tat peptide of HIV enhanced the cellular uptake by dendritic cells [34]. Similarly, Quer et al. synthesized poly(g-benzyl-l-glutamate)-K (PBLG50-K) polymersomes and tested them as an adjuvant for influenza haemagglutinin (HA) antigen [35]. For targeted delivery to antigen-presenting cells, specifically to dendritic cells, POP-sulphide-based nanoparticles have been designed. These nanoparticles can be easily taken up in to lymphatic system and retained in lymph nodes for a longer period of time. A total of 40–50% nodal resident dendritic cells and other antigen-presenting cells internalized these nanoparticles [106]. The advantage of using polysulphide-based particles is that they are stimuli-responsive and can encapsulate hydrophobic drugs efficiently [107].
2.2.6. Polymethacrylates
Polymethacrylic-acid-based nanoparticles were shown to be effective as adjuvants for inactivated HIV-2 antigen compared with several other conventional adjuvants, including alum and Freund's adjuvant [108]. They have been reported to enhance immune responses against different antigens, including influenza virus and bovine serum albumin [36]. The optimum methylmethacrylic acid concentration for enhancing antibody response against influenza virus was 2 per cent w/v. Above this concentration, immune responses declined. This can be explained better by antigen protection at higher concentrations of polymer. Furthermore, antigen concentration also affects the antibody response. Higher antigenic doses induced better antibody responses than lower amounts of antigen [109]. Cytokine induction and the adjuvant effect of PMMA particles was also demonstrated by Lou et al. [37] in DNA vaccination. In this vaccination procedure, TNF-α production was enhanced when macrophages were exposed to PMMA particles. They have synthesized a number of PMMA particles for DNA vaccination, and different levels of tumour protection effect were observed, which was dependent on the size and charge of the particles. Kreuter & Liehl [110] also tested the adjuvant potential of polymethylmethacrylate and polyacrylamide copolymer-based nanocapsules using inactivated influenza virus vaccine with an increased vaccine potential against lethal influenza infection. Besides protection, polymers were also effective in the induction of antibody responses. Recently, cationic poly(2-aminoethylmethacrylate) polymers with controlled chain length and defined molecular weight were synthesized and characterized for delivery of DNA vaccine to dendritic cells [111]. In another study, pH-sensitive polydiethylaminoethyl methacrylate core polyaminoethyl methacrylate shell nanoparticles were designed for targeted delivery of membrane impermeable molecules to dendritic cells [112]. Cytosolic delivery of antigens by these particles decreased the dose required for the activation of immune responses, significantly [113].
2.2.7. Polyglycolic-co-lactides
The adjuvant potential of PLGA using the particulate system [38,39] has been well documented. This polymer enhanced the uptake of delivered antigens by APCs [114,115]. Besides antigen presentation, numerous antigens in the form of proteins, peptides, viruses or DNA can easily be encapsulated in the form of nanoparticles [116]. In such vaccines, controlled release of antigen(s) for a longer period of time can effectively activate the immune responses, thereby avoiding booster doses required for the induction of protective immunity [117]. PLGA particles can also act as the delivery system for more than one type of antigen or combinations of antigen–adjuvant formulations in the same particle [118]. Furthermore, PLGA microparticles can retain the antigens in local lymph nodes and protect them from proteolytic degradation, which ensures longer retention of antigen. It has been shown that low doses of antigen are effectively delivered using PLGA particles for strong induction of T cell responses [119]. In addition, these particles can also be used for delivering exogenous antigens via MHC class I complexes to CD8+ cells [120]. An additional advantage of PLGA nanoparticles is their functionalization with ligands such as antibodies, proteins and polysaccharides binding to membrane receptors of the cells, which is relatively easier than other polymers [121]. Uptake of PLGA particles depend on the characteristic features of the delivered antigen and also on the size, shape, charge and nature of the particle surface [122]. Out of these properties, size is one of the critical factors that decides the uptake of antigen loaded nanoparticles. The optimum dimensions of nanoparticles are yet to be confirmed, but 20–100 nm is enough for internalization. Apart from the antigen uptake via APCs, peripheral lymph nodes can also directly internalize these particles [43,123]. Recently, PLGA was mixed with alginate to improve the encapsulation efficiency. The incorporated alginate also elicited higher humoral and cellular response after immunization with two malarial synthetic peptides, SPf66 and S3, in BALB/c mice. Furthermore, PLGA with alginate modified with RGD peptide have been shown to enhance immunogenicity by cell-specific targeting [124]. PLGA microparticles coated with protamine significantly enhanced the immunogenicity of weak antigen in comparison with uncoated particles. The protamine moiety facilitates better cell penetration of these particles [125].
The efficacy of PLGA-based microspheres also has been tested for immunotherapy against experimental tumours. The mice vaccinated with PLGA-MS loaded ovalbumin and CpG oligodeoxynucleotides elicited a strong cytotoxic T-lymphocyte response [126]. In another study, the efficacy of PLGA particles with poly-l-arginine was compared with polyelectrolyte microcapsules in the induction of Th1/Th2 responses [127].
2.2.8. Polycaprolactones
Poly-ε-caprolactone (PEC) is another biocompatible and biodegradable synthetic polymer, which is used as an adjuvant. Unlike PLGA polymer, PEC degrades very slowly and does not generate an acidic environment after its degradation. The good biodegradability and low acidic pH makes PEC a potential adjuvant candidate and carrier for different vaccines. The adjuvant property of PEC-based microparticles was demonstrated with an antigen of Schistosoma mansoni for the induction of immunity after a single administration [42]. Compared with PLGA, PEC particles encapsulated with a similar antigen induced immune responses for a longer duration after oral or nasal antigen administration [123]. Better adjuvant properties of PEC were again proven in the delivery of antigenic extract (HS) from Brucella ovis either subcutaneously or per orally in BALB/c mice. Moreover, PEC particles with HS extract were found to interact more strongly with mucosal and Peyer's patches than PLGA. PEC-induced immune responses are of the Th1-type, while PLGA-induced Th2 responses are characterized by significant production of IL-4 levels. Furthermore, PEC induced higher release of IFN-γ and IL-2 cytokines than PLGA [43]. PEC particles were also proven to be efficient carriers for Diphtheria toxoid in mucosal vaccines compared to PLGA, and the higher uptake of PEC particles is due to the more hydrophobic nature of the PEC polymer [128].
2.2.9. Polyvinylpyrrolidone
Another biocompatible polymer polyvinylpyrrolidone (PVP) was used as an adjuvant in a few studies. PVP was used successfully in entrapping an antigen extracted from Aspergillus fumigates and was capable of significantly inducing IgG levels compared to free antigen. Interestingly, the IgE response to PVP particles loaded with antigen was lower than the free antigen [44].
2.2.10. Cationic polymers
In general, cationic polymers, polyethylamines, were used in DNA delivery and immunization of various antigens via different routes. The approaches for DNA delivery usually involve injection of DNA either in solution or with cationic polymers/lipids. Efficient delivery of DNA to APCs in such a way could enhance the efficacy of nucleic acid and produce a strong immune response [45]. Such cationic polymer-based microparticles can also be synthesized via the incorporation of DNA non-covalently [129].
Adjuvant potential of polymers in the induction of autoimmunity, mainly for the development of diseases models, has recently been explored (table 2). Animal models of autoimmune diseases have similarities to human disease phenotypes and are thus essential to delineate the disease pathways, genetics and, for developing and testing drug targets. Autoimmune disease models are developed mainly by disrupting the immune homeostasis either via immunization with autoantigens, spontaneous or induced genetic mutations or by using surgical procedures. Autoimmune diseases can be induced by immunization with polymers and autoantigens successfully. LPS is the first polymer that has been used in the activation of immune responses, which depend on time and dose of administration along with an antigen [141]. β-Glucans and zymosan are other natural polymers isolated form microbes that have been proven to be potential adjuvants for the development of autoimmune diseases [142,143]. Parallel to natural polymers, a few synthetic block copolymers of POP and POE has also been demonstrated for their adjuvant capacity in the development of myasthenia gravis, when injected along with torpedo acetylcholine receptor [136]. Recently, we have developed a synthetic polymer-based poly-N-isopropylacrylamide (PNiPAAm) adjuvant for the development of collagen-induced arthritis. When collagen type II (CII) purified from rat chondrosarcoma was injected with PNiPAAm, it efficiently activated the immune response in several different mouse strains and subsequently induced arthritis [137,138]. Most importantly, PNiPAAm was found to induce the immune responses independent of toll-like receptors.
Table 2.
Table 2.
Polymeric adjuvants used in autoimmunity.
In adjuvant research, few natural polymers proved to be efficient adjuvants for the induction of autoimmune responses. LPS is the first natural polymer that has been used as an adjuvant and its immunomodulation activity was first reported by Claman [144], who used LPS in conjunction with a T-dependent antigen. Recently, the adjuvant properties of LPS have been comprehensively characterized. LPS is a component of the cell wall of Gram-negative bacteria and used widely as the B cell mitogen [145]. It is composed of O antigen (polysaccharides) and lipid A moiety linked by a trisaccharide unit [146]. The mode of action of LPS is not fully understood yet, but lipid A is responsible for mitogenic activity and toxicity. In earlier experiments, it was demonstrated that LPS in conjunction with sheep red blood cells was capable of inducing significant antibody responses [147]. The mode of action of LPS is mainly via the humoral immune response to various T-independent antigens. Enhancement of antibody responses was observed when LPS and antigen were injected at the same time, and it was mainly dependent on the amount of antigen injected. Two- or threefold antibody increase was observed at the optimal amount of antigen, while the effect was strongest up to 40-fold when a low dose of antigen was given [130]. The effect was almost suppressed or absent when LPS was given 1–2 days after antigen injection [148]. Co-oral [131,149] administration of LPS along with CII enhanced both CII-specific antibody production and T-cell responses leading to a more chronic arthritis.
In this respect, β-glucans, another natural polysaccharide extracted from Candida albicans, has been tested as an adjuvant in the induction of experimental arthritis. β-Glucan is the polymer of d-glucose monomeric units linked via β-type glycosidic linkage and mainly occurs in variety of microbes. β-Glucan as an adjuvant has immunologic properties, which depend on solubility, molecular weight, degree of branching and conformation of the polymer [150152]. Additionally, β-glucan has the ability to activate leukocytes, production of reactive oxygen species (ROS) and TNF-α cytokine [132,153]. Mice injected with β-glucan polymer are able to produce autoantibodies [149]. Hida and co-workers studied autoimmunity of the particulate form of oxidized β-glucans isolated from C. albicans in DBA/1 mice [131]. In vitro, these glucans activated the alternative complement pathway, enhanced vascular permeability and induced a higher level of IL-6 production by macrophages [152]. Furthermore, they have tested adjuvant activity of a water-soluble β-glucan fraction released from C. albicans and this fraction accelerated cytokine synthesis and activated immune cells leading to autoimmune arthritis [150,151]. Similarly, the adjuvant potential of β-glucan polymer isolated from a pathogenic fungus Laminaria digitata was tested in the spontaneous SKG model of autoimmune arthritis. These mice were unable to develop spontaneous arthritis in a specific pathogen-free environment but were able to develop arthritis after an injection of β-glucans intraperitoneally [132].
Furthermore, zymosan has also been demonstrated to activate autoimmune responses. Zymosan is a polysaccharide extracted from the cell wall of the yeast, Saccharomyces cerevisiae and it mainly contains β-1,3-glucan residues. As an adjuvant, zymosan binds to the TLR-2 receptor and activates the NF-κB signalling pathway, thereby inducing inflammatory cytokine production [153,154]. β-Glucan derived from zymosan and their brief oxidation product act as a powerful adjuvant (carbohydrate adjuvant) for collagen-induced arthritis and at first, Keystone et al. [133] studied the arthritogenicity of zymosan independently. Induction of arthritis was mediated via activation of the alternative complement pathway and macrophages, through binding to the membrane receptor dectin-1.
In this direction, the potential effect of lipomannan as an adjuvant has been analysed in collagen-antibody-induced arthritis, a model widely used to study the effector phase of arthritis without involving the priming phase. Lipomannan enhanced arthritis in the presence of functional phagocytes, which produced more ROS when injected with a cocktail of anti-collagen antibodies binding to well-defined CII epitopes by mainly interacting with TLR2, and the disease phenotype was mainly from the activity of granulocytes [134,135].
3.2. Synthetic polymers
Similarly, the adjuvant potential of synthetic polymers was studied using animal models of auotimmune diseases. Shenoy and Christadoss used TiterMax non-ionic block copolymer as an adjuvant with torpedo acetylcholine receptor antigen in C57BL/6 mice to induce autoimmune myasthenia gravis disease, characterized by weakness in muscles with electrophysiological defects with a significant increase in serum IgG levels [136]. Non-ionic block polymers are a copolymer of hydrophobic POP and hydrophilic POE blocks [74]. Block copolymers with high hydrophobicity were showing greater adjuvant potential, which could be changed by altering hydrophobicity and hydrophilicity content of the copolymer. These copolymers act as surface-active agents and form a stable water-in-oil emulsion, which act as a depot for slow release of antigen through the polymer.
Very recently, the adjuvant potential of temperature responsive PNiPAAm has been studied in the development of murine rheumatoid arthritis. PNiPAAm was synthesized through free radical polymerization (having a molecular weight of 120 kDa) and purified through repeated cycles of cooling and heating. This polymer, when injected with CII showed gelation properties, which led to clear precipitation and subsequent slow release of antigen (figure 2). More importantly, the polymer alone was unable to induce an immune response and only mice immunized with the polymer mixed with CII induced antigen-specific autoimmunity leading to polyarthritis. All the mice immunized with PNiPAAm-CII developed an antibody response significantly comprising of all the major IgG subclasses and an antigen-specific recall immune response was also observed using lymphocyte proliferation assay. All polymer immunized arthritic mice had massive infiltration of effector cells, including macrophages, neutrophils, eosinophils and osteoclasts, with extensive damage to the joint architecture. CII mixed with the polymer retained its native confirmation, which is a requirement for arthritis induction. CII mixed with a high-molecular-weight form of moderately hydrophobic PNiPAAm induced a significantly higher anti-CII response compared with covalently linked CII and polymer. Interestingly, all the polymer-CII immunized TLR deficient mice developed anti-CII antibodies, demonstrating adjuvancity of PNiPAAm could be independent of TLR pathways. This polymer PNiPAAm grafted with gelatine has been also used as a scaffold to support growth of primary chondrocytes for regeneration of cartilage [155].
Figure 2.
Figure 2.
Schematic of reversible behaviour of temperature responsive poly-N-isopropylacrylamide (PNiPAAm). Below the lower critical solution temperature, PNiPAAm-antigen mixture is in the soluble state and it becomes a precipitate above this temperature.
Despite the use of polymers in animal models, autoimmunity has also been reported owing to polymer implants. Lately, a new autoimmune syndrome induced by adjuvants has been reported. A well-known example is silicone polymer implantation [156]. Patients with silicone implants were developing a high level of anti-silicone antibodies in the surrounding tissues [139], and the presence of autoantibodies was demonstrated via immuno-fluorescence staining in the capsular tissue [140]. In another study, the presence of autoantibodies, including rheumatoid factor and anti-dsDNA antibodies, was observed in experimental mice after silicone implantation, leading to the development of autoimmune diseases [157]. Lidar and co-workers extensively studied autoimmunity in symptomatic women, who had silicone breast implants compared with asymptomatic women [158] and a 20 per cent increase in IgG titre was observed, and most of the antibodies were against dsDNA, ss-DNA, silicone and collagen type II. Also, chronic fatigue syndrome was triggered in patients with hepatitis B vaccination after silicone implantation [159]. Similarly, various autoimmune diseases including RA, systemic lupus erythematosus and systemic sclerosis were observed in several patients who had undergone silicone implantation [160]. At the cellular level, various phenotypic and functional alterations of T-cell subsets, B-cell activation, autoantibodies directed against endothelial and nuclear antigens were observed as a result of the implanted silicone polymer [161].
In conclusion, polymers as an adjuvant have the ability to enhance the immunogenicity of antigens in vaccination as well as in the induction of autoimmune responses. They can induce immune responses efficiently through different signalling mechanisms (toll-like receptors, inflammasome pathways) and offer the possibility of substituting bacterial-based adjuvants, which may cause toxicity and undesired activation of the immune system. Polymers have the ability to induce both humoral and cellular immune responses, when given along with an antigen, although they are not capable of eliciting any immune response on their own. Adjuvant potential of polymers depends on the solubility, molecular weight, degree of branching and conformation of the polymer used. Usually, they work on the principle of depot generation for slow release of the antigen for a longer period of time and act as an immuno-modulator via strong antigen presentation. Thus, polymeric adjuvants are highly valuable for better vaccination strategies and in studying basic pathogenic mechanisms involved in autoimmune diseases.
Acknowledgements
Supported by Swedish Rheumatism Association, King Gustaf V:s 80-years foundation, Swedish Research Council and Karolinska Institute funding agencies.
1. Bomford R. 1998. Will adjuvants be needed for vaccines of the future. In Modulation of the immune response to vaccine antigens Dev Biol Stand, vol. 92 (eds Brown F, Haaheim LR, editors. ), pp. 13–18 Basel, Switzerland: Karger.
2. Vogel FR. 1998. Adjuvants in perspective. In Modulation of the immune response to vaccine antigens Dev Biol Stand, vol. 92 (eds Brown F, Haaheim LR, editors. ), pp. 241–248 Basel, Switzerland: Karger.
3. Nandakumar KS, Holmdahl R. 2006. Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis. Arthritis Res. Ther. 8, 223. (doi:10.1186/ar2089) doi: 10.1186/ar2089. [PMC free article] [PubMed] [Cross Ref]
4. Lindblad EB. 1995. Aluminium adjuvants. In The theory and practical application of adjuvants (ed. Stewart-Tull DES, editor. ), pp. 21–35 Chichester, UK: John Wiley & Sons Ltd.
5. Johnson HE, DeAvila DM, Chang F, Reeves JJ. 1988. Active immunization of heifers against luteinizing hormone-releasing hormone, human chorionic gonadotropin and bovine luteinizing hormone. J. Anim. Sci. 66, 719–726. [PubMed]
6. Jacobs DM. 1979. Synergy between T cell-replacing factor and bacterial lipopolysaccharide (LPS) in the primary antibody response in vitro: a model for lipopolysaccharide adjuvant action. J. Immunol. 122, 1421–1426. [PubMed]
7. Heufler C, Koch F, Schuler G. 1988. Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J. Exp. Med. 167, 700–705 (doi:10.1084/jem.167.2.700) doi: 10.1084/jem.167.2.700. [PMC free article] [PubMed] [Cross Ref]
8. Segal BM, Chang JT, Shevach EM. 2000. CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J. Immunol. 164, 5683–5688. [PubMed]
9. Freund J. 1956. The mode of action of immunologic adjuvants. Adv. Tuberc. Res. 7, 130–148. [PubMed]
10. Matthys P, Vermeire K, Billiau A. 2001. Mac-1+ myelopoiesis induced by complete Freund's adjuvant (CFA): a clue to the paradoxical effects of IFN-γ in autoimmune disease models. Trends Immunol. 22, 367–371 (doi:10.1016/S1471-4906(01)01937-8) doi: 10.1016/S1471-4906(01)01937-8. [PubMed] [Cross Ref]
11. Heeger PS, Forsthuber T, Shive C, Biekert E, Genain C, Hofstetter HH, Karulin A, Lehmann PV. 2000. Revisiting tolerance induced by autoantigen in incomplete Freund's adjuvant. J. Immunol. 164, 5771–5781. [PubMed]
12. Stills HF, Bailey MQ. 1991. The use of Freund's complete adjuvant. Lab. Anim. 20, 25–30.
13. Bauer C, et al. 2010. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 59, 1192–1199 (doi:10.1136/gut.2009.197822) doi: 10.1136/gut.2009.197822. [PubMed] [Cross Ref]
14. Houston WE, Crabbs CL, Kremer RJ, Springer JW. 1976. Adjuvant effects of diethylaminoethyl-dextran. Infect. Immun. 13, 1559–1562. [PMC free article] [PubMed]
15. Bachelder EM, Beaudette TT, Broaders KE, Frechet JMJ, Albrecht MT, Mateczun AJ, Ainslie KM, Pesce JT, Keane-Myers AM. 2010. In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants. Mol. Pharm. 7, 826–835 (doi:10.1021/mp900311x) doi: 10.1021/mp900311x. [PMC free article] [PubMed] [Cross Ref]
16. Drandarska I, Kussovski V, Nikolaeva S, Markova N. 2005. Combined immunomodulating effects of BCG and Lentinan after intranasal application in guinea pigs. Int. Immunopharmacol. 5, 795–803 (doi:10.1016/j.intimp.2004.12.008) doi: 10.1016/j.intimp.2004.12.008. [PubMed] [Cross Ref]
17. Guo Z, Hu Y, Wang D, Ma X, Zhao X, Zhao B, Wang J, Liu P. 2009. Sulfated modification can enhance the adjuvanticity of lentinan and improve the immune effect of ND vaccine. Vaccine 27, 660–665 (doi:10.1016/j.vaccine.2008.11.038) doi: 10.1016/j.vaccine.2008.11.038. [PubMed] [Cross Ref]
18. Cooper PD, Steele EJ. 1988. The adjuvanticity of γ inulin. Immunol. Cell Biol. 66, 345–352 (doi:10.1038/icb.1988.45) doi: 10.1038/icb.1988.45. [PubMed] [Cross Ref]
19. Cristillo AD, et al. 2011. Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations. J. Gen. Virol. 92, 128–140 (doi:10.1099/vir.0.023242-0) doi: 10.1099/vir.0.023242-0. [PMC free article] [PubMed] [Cross Ref]
20. Stambas J, Pietersz G, McKenzie IF, Cheers C. 2002. Oxidised mannan as a novel adjuvant inducing mucosal IgA production. Vaccine 20, 1068–1078 (doi:10.1016/S0264-410X(01)00456-X) doi: 10.1016/S0264-410X(01)00456-X. [PubMed] [Cross Ref]
21. Lee JK, Lee MK, Yun YP, Kim Y, Kim JS, Kim YS, Kim K, Han SS, Lee CK. 2001. Acemannan purified from Aloe vera induces phenotypic and functional maturation of immature dendritic cells. Int. Immunopharmacol. 1, 1275–1284 (doi:10.1016/S1567-5769(01)00052-2) doi: 10.1016/S1567-5769(01)00052-2. [PubMed] [Cross Ref]
22. Prego C, Paolicelli P, Díaz B, Vicente S, Sánchez A, González-Fernández A, Alonso MJ. 2010. Chitosan-based nanoparticles for improving immunization against hepatitis B infection. Vaccine 28, 2607–2614 (doi:10.1016/j.vaccine.2010.01.011) doi: 10.1016/j.vaccine.2010.01.011. [PubMed] [Cross Ref]
23. Ghendon Y, et al. 2009. Evaluation of properties of chitosan as an adjuvant for inactivated influenza vaccines administered parenterally. J. Med. Virol. 81, 494–506 (doi:10.1002/jmv.21415) doi: 10.1002/jmv.21415. [PubMed] [Cross Ref]
24. Kotze AF, Luessen HL, de Leeuw BJ, de Boer BG, Verhoef JC, Junginger HE. 1997. N-trimethyl chitosan chloride as a potential absorption enhancer across mucosal surfaces: in vitro evaluation in intestinal epithelial cells (Caco-2). Pharm. Res. 14, 1197–1202 (doi:10.1023/A:1012106907708) doi: 10.1023/A:1012106907708. [PubMed] [Cross Ref]
25. Akagi T, Kaneko T, Kida T, Akashi M. 2005. Preparation and characterization of biodegradable nanoparticles based on poly(γ-glutamic acid) with l-phenylalanine as a protein carrier. J. Control. Release 108, 226–236 (doi:10.1016/j.jconrel.2005.08.003) doi: 10.1016/j.jconrel.2005.08.003. [PubMed] [Cross Ref]
26. Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V. 2002. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines 1, 111–118 (doi:10.1586/14760584.1.1.111) doi: 10.1586/14760584.1.1.111. [PubMed] [Cross Ref]
27. Andrianov AK, Marin A, Chen J. 2006. Synthesis, properties, and biological activity of poly[di(sodium carboxylatoethylphenoxy)phosphazene]. Biomacromolecules 7, 394–399 (doi:10.1021/bm050790a) doi: 10.1021/bm050790a. [PubMed] [Cross Ref]
28. McNeal MM, Rae MN, Ward RL. 1999. Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus. Vaccine 17, 1573–1580 (doi:10.1016/S0264-410X(98)00359-4) doi: 10.1016/S0264-410X(98)00359-4. [PubMed] [Cross Ref]
29. De-Geest BG, et al. 2012. Polymeric multilayer capsule-mediated vaccination induces protective immunity against cancer and viral infection. ACS Nano 6, 2136–2149 (doi:10.1021/nn205099c) doi: 10.1021/nn205099c. [PubMed] [Cross Ref]
30. Chen CH, et al. 2012. Liposome-based polymer complex as a novel adjuvant: enhancement of specific antibody production and isotype switch. Int. J. Nanomed. 7, 607–621. [PMC free article] [PubMed]
31. Conde BC, Schiltz E, Yu J, Minion FC, Phillips GJ, Wannemuehler MJ, Narasimhan B. 2010. Encapsulation into amphiphilic polyanhydride microparticles stabilizes Yersinia pestis antigens. Acta Biomater. 6, 3110–3119 (doi:10.1016/j.actbio.2010.01.040) doi: 10.1016/j.actbio.2010.01.040. [PubMed] [Cross Ref]
32. Yoncheva K, Lizarraga E, Irache JM. 2005. Pegylated nanoparticles based on poly(methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive properties. Eur. J. Pharm. Sci. 24, 411–419 (doi:10.1016/j.ejps.2004.12.002) doi: 10.1016/j.ejps.2004.12.002. [PubMed] [Cross Ref]
33. Todd CW, Pozzi LAM, Guarnaccia JR, Balasubramanian M, Henkf WJ, Youngert LE, Newman MJ. 1997. Development of an adjuvant-active nonionic block copolymer for use in oil-free subunit vaccines formulations. Vaccine 15, 564–570 (doi:10.1016/S0264-410X(97)00209-0) doi: 10.1016/S0264-410X(97)00209-0. [PubMed] [Cross Ref]
34. Christian NA, et al. 2007. Tat-functionalized near-infrared emissive polymersomes for dendritic cell labeling. Bioconjug. Chem. 18, 31–40 (doi:10.1021/bc0601267) doi: 10.1021/bc0601267. [PubMed] [Cross Ref]
35. Quer CB, Marsden HR, Romeijn S, Zope H, Kros A, Jiskoot W. 2011. Polymersomes enhance the immunogenicity of influenza subunit vaccine. Polym. Chem. 2, 1482–1485 (doi:10.1039/c1py00010a) doi: 10.1039/c1py00010a. [Cross Ref]
36. Kreuter J. 1992. Physicochemical characterization of nanoparticles and their potential for vaccine preparation. Vac. Res. 1, 93–98.
37. Lou PJ, Cheng WF, Chung YC, Cheng CY, Chiu LH, Young TH. 2009. PMMA particle-mediated DNA vaccine for cervical cancer. J. Biomed. Mater. Res. A 88, 849–857 (doi:10.1002/jbm.a.31919) doi: 10.1002/jbm.a.31919. [PubMed] [Cross Ref]
38. Saini V, Jain V, Sudheesh MS, Jaganathan KS, Murthy PK, Kohli DV. 2011. Comparison of humoral and cell mediated immune responses to cationic PLGA microspheres containing recombinant hepatitis B antigen. Int. J. Pharm. 408, 50–57 (doi:10.1016/j.ijpharm.2011.01.045) doi: 10.1016/j.ijpharm.2011.01.045. [PubMed] [Cross Ref]
39. Moon JJ, Suh H, Polhemus ME, Ockenhouse CF, Yadava A, Irvine DJ. 2012. Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine. PLoS ONE 7, e31472. (doi:10.1371/journal.pone.0031472) doi: 10.1371/journal.pone.0031472. [PMC free article] [PubMed] [Cross Ref]
40. Shi L, Caulfield MJ, Chern RT, Wilson RA, Sanyal G, Volkin DB. 2002. Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres. J. Pharm. Sci. 91, 1019–1035 (doi:10.1002/jps.10042) doi: 10.1002/jps.10042. [PubMed] [Cross Ref]
41. He XW, et al. 2005. Induction of mucosal and systemic immune response by single-dose oral immunization with biodegradable microparticles containing DNA encoding HBsAg. J. Gen. Virol. 86, 601–610 (doi:10.1099/vir.0.80575-0) doi: 10.1099/vir.0.80575-0. [PubMed] [Cross Ref]
42. Benoit MA, Baras B, Poulain-Godefroy O, Schacht AM, Capron A, Gillard J, Riveau G. 1998. Evaluation of the antibody response after oral immunization by microparticles containing as antigen from Schistosoma mansoni. In Biomedical science and technology recent developments in the pharmaceutical and medical sciences (eds Hincal A, Kas H, editors. ), pp. 137–144 New York, NY: Plenum.
43. Murillo M, Goni MM, Irache JM, Arangoa MA, Blasco JM, Gamazo C. 2002. Modulation of the cellular immune response after oral or subcutaneous immunization with microparticles containing Brucella ovis antigens. J. Control. Release 85, 237–246 (doi:10.1016/S0168-3659(02)00276-6) doi: 10.1016/S0168-3659(02)00276-6. [PubMed] [Cross Ref]
44. Madan T, Munshi N, De TK, Maitra A, Sarma PU, Aggarwal SS. 1997. Biodegradable nanoparticles as a sustained release system for the antigens/allergens of Aspergillus fumigatus: preparation and characterisation. Int. J. Pharm. 159, 135–147 (doi:10.1016/S0378-5173(97)00278-0) doi: 10.1016/S0378-5173(97)00278-0. [Cross Ref]
45. Mastrobattista E, Hennink WE. 2012. Polymers for gene delivery charged for success. Nat. Mater. 11, 10–12 (doi:10.1038/nmat3209) doi: 10.1038/nmat3209. [PubMed] [Cross Ref]
46. Kaistha J, Sockey J, Singh S, Kumar S, John PC, Sharma NC. 1996. Adjuvant effect of DEAE-dextran and tetanus toxoid on whole cell heat inactivated phenol preserved typhoid vaccine. Indian J. Pathol. Immunol. 39, 287–292. [PubMed]
47. Irinoda K, Masihi KN, Chihara G, Kaneko Y, Katori T. 1992. Stimulation of microbicidal host defence mechanisms against aerosol influenza virus infection by lentinan. Int. J. Immunopharmacol. 14, 971–977 (doi:10.1016/0192-0561(92)90140-G) doi: 10.1016/0192-0561(92)90140-G. [PubMed] [Cross Ref]
48. Wang J, Zhou ZD, Xia DJ. 2007. Study on effect of lentinan in enhancing anti-tumor action of dendritic cytoma vaccine and its mechanism. Zhongguo Zhong Xi Yi Jie He Za Zhi 27, 60–64. [PubMed]
49. Bruley-Rosset M, Florentin I, Mathe G. 1976. In vivo and in vitro macrophage activation by systemic adjuvants. Agents Actions 6, 251–255 (doi:10.1007/BF01972217) doi: 10.1007/BF01972217. [PubMed] [Cross Ref]
50. Cooper PD, Carter M. 1986. Anti-complementary action of polymorphic ‘solubility forms’ of particulate inulin. Mol. Immunol. 23, 895–901 (doi:10.1016/0161-5890(86)90075-1) doi: 10.1016/0161-5890(86)90075-1. [PubMed] [Cross Ref]
51. Cooper PD, Petrovsky N. 2011. δ inulin: a novel, immunologically-active, stable packing structure comprising β-d-[2 → 1] poly(fructo-furanosyl) α-d-glucose polymers. Glycobiology 21, 595–606 (doi:10.1093/glycob/cwq201) doi: 10.1093/glycob/cwq201. [PMC free article] [PubMed] [Cross Ref]
52. Lobigs M, Pavy M, Hall RA, Lobigs P, Cooper P, Komiya T, Toriniwa H, Petrovsky N. 2010. An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses. J. Gen. Virol. 91, 1407–1417 (doi:10.1099/vir.0.019190-0) doi: 10.1099/vir.0.019190-0. [PMC free article] [PubMed] [Cross Ref]
53. Petrovsky N, Cooper PD. 2011. Carbohydrate-based immune adjuvants. Expert Rev. Vaccines 10, 523–537 (doi:10.1586/erv.11.30) doi: 10.1586/erv.11.30. [PMC free article] [PubMed] [Cross Ref]
54. Thiel S, Gadjeva M. 2009. Humoral pattern recognition molecules: mannan-binding lectin and ficolins. Adv. Exp. Med. Biol. 653, 58–73 (doi:10.1007/978-1-4419-0901-5_5) doi: 10.1007/978-1-4419-0901-5_5. [PubMed] [Cross Ref]
55. Takahara K, Yashima Y, Omatsu Y, Yoshida H, Kimura Y, Kang YS, Steiman RM, Park CG, Inaba K. 2004. Functional comparison of the mouse DC-SIGN, SIGNR1, SIGNR3 and Langerin, C-type lectins. Int. Immunol. 16, 819–829 (doi:10.1093/intimm/dxh084) doi: 10.1093/intimm/dxh084. [PubMed] [Cross Ref]
56. Sheng KC, Pouniotis DS, Wright MD, Tang CK, Lazoura E, Pietersz GA, Apostolopoulos V. 2006. Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology 118, 372–383 (doi:10.1111/j.1365-2567.2006.02384.x) doi: 10.1111/j.1365-2567.2006.02384.x. [PubMed] [Cross Ref]
57. McKenzie IF, Apostolopoulos V, Lees C, Xing PX, Lofthouse S, Osinski C, Popovski V, Acres B, Pietersz G. 1998. Oxidised mannan antigen conjugates preferentially stimulate T1 type immune responses. Vet. Immunol. Immunopathol. 63, 185–190 (doi:10.1016/S0165-2427(98)00094-4) doi: 10.1016/S0165-2427(98)00094-4. [PubMed] [Cross Ref]
58. Yoshitomi H, et al. 2005. A role for fungal β-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. J. Exp. Med. 201, 949–960 (doi:10.1084/jem.20041758) doi: 10.1084/jem.20041758. [PMC free article] [PubMed] [Cross Ref]
59. Hashimoto M, et al. 2010. Complement drives Th17 cell differentiation and triggers autoimmune arthritis. J. Exp. Med. 207, 1135–1143 (doi:10.1084/jem.20092301) doi: 10.1084/jem.20092301. [PMC free article] [PubMed] [Cross Ref]
60. Arca HC, Gunbeyaz M, Senel S. 2009. Chitosan-based systems for the delivery of vaccine antigens. Expert Rev. Vaccines 8, 937–953 (doi:10.1586/erv.09.47) doi: 10.1586/erv.09.47. [PubMed] [Cross Ref]
61. Wen ZS, Xu YL, Zou XT, Xu ZR. 2011. Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. Mar. Drugs 9, 1038–1055 (doi:10.3390/md9061038) doi: 10.3390/md9061038. [PMC free article] [PubMed] [Cross Ref]
62. Zhao K, Shi X, Zhao Y, Wei H, Sun Q, Huang T, Zhang X, Wang Y. 2011. Preparation and immunological effectiveness of a swine influenza DNA vaccine encapsulated in chitosan nanoparticles. Vaccine 29, 8549–8556 (doi:10.1016/j.vaccine.2011.09.029) doi: 10.1016/j.vaccine.2011.09.029. [PubMed] [Cross Ref]
63. Borges O, Cordeiro-da-Silva A, Tavares J, Santarém N, de Sousa A, Borchard G, Junginger HE. 2008. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur. J. Pharm. 69, 405–416 (doi:10.1016/j.ejpb.2008.01.019) doi: 10.1016/j.ejpb.2008.01.019. [PubMed] [Cross Ref]
64. Gong YF, Xie Y, Zhou NJ, Chen J, Zhou XJ, Lu NH, Wang CW. 2007. Cellular immunity induced by H. pylori vaccine with chitosan as adjuvant. Chin. J. Cell Mol. Immunol. 23, 595–599. [PubMed]
65. Sayin B, Somavarapu S, Li XW, Sesardic D, Senel S, Alpar OH. 2009. TMC–MCC (N-trimethyl chitosan–mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccine. Eur. J. Pharm. Sci. 38, 362–369 (doi:10.1016/j.ejps.2009.08.010) doi: 10.1016/j.ejps.2009.08.010. [PubMed] [Cross Ref]
66. Verheul RJ, Slütter B, Bal SM, Bouwstra JA, Jiskoot W, Hennink WE. 2011. Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination. J. Control. Release 156, 46–52 (doi:10.1016/j.jconrel.2011.07.014) doi: 10.1016/j.jconrel.2011.07.014. [PubMed] [Cross Ref]
67. Uto T, Akagi T, Yoshinaga K, Toyama M, Akashi M, Baba M. 2011. The induction of innate and adaptive immunity by biodegradable poly(γ-glutamic acid) nanoparticles via a TLR4 and MyD88 signaling pathway. Biomaterials 32, 5206–5212 (doi:10.1016/j.biomaterials.2011.03.052) doi: 10.1016/j.biomaterials.2011.03.052. [PubMed] [Cross Ref]
68. Kurosaki T, Kitahara T, Nakamura T, Nishida K, Fumoto S, Kodama Y, Nakagawa H, Higuchi N, Sasaki H. 2012. Development of effective cancer vaccine using targeting system of antigen protein to APCs. Pharm. Res. 29, 483–489 (doi:10.1007/s11095-011-0571-x) doi: 10.1007/s11095-011-0571-x. [PubMed] [Cross Ref]
69. Chang JCC, Diveley JP, Savary JR, Jensen FC. 1998. Adjuvant activity of incomplete Freund's adjuvant. Adv. Drug Deliv. Rev. 32, 173–186 (doi:10.1016/S0169-409X(98)00009-X) doi: 10.1016/S0169-409X(98)00009-X. [PubMed] [Cross Ref]
70. Vogel FR, Powell MF. 1995. A compendium of vaccine adjuvants and excipients. In Vaccine design: the subunit and adjuvant approach (eds Powell MF, Newman MJ, editors. ), pp. 141–228 New York, NY: Plenum.
71. Podda A. 2001. The adjuvanted influenza vaccines with novel adjuvants: experience with MF59-adjuvanted vaccine. Vaccine 19, 2673–2680 (doi:10.1016/S0264-410X(00)00499-0) doi: 10.1016/S0264-410X(00)00499-0. [PubMed] [Cross Ref]
72. Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, Devaster JM, Leroux-Roels G. 2007. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370, 580–589 (doi:10.1016/S0140-6736(07)61297-5) doi: 10.1016/S0140-6736(07)61297-5. [PubMed] [Cross Ref]
73. Gaucher G, Poreba M, Ravenelle F, Leroux JC. 2007. Poly(N-vinyl-pyrrolidone)-block-poly(d,l-lactide) as polymeric emulsifier for the preparation of biodegradable nanoparticles. J. Pharm. Sci. 96, 1763–1775 (doi:10.1002/jps.20833) doi: 10.1002/jps.20833. [PubMed] [Cross Ref]
74. Newman MJ, Balusubramanian M, Todd CW. 1998. Development of adjuvant-active nonionic block copolymers. Adv. Drug Deliv. Rev. 32, 199–223 (doi:10.1016/S0169-409X(98)00011-8) doi: 10.1016/S0169-409X(98)00011-8. [PubMed] [Cross Ref]
75. Jeong B, Bae YH, Lee DS, Kim SW. 1997. Biodegradable block copolymers as injectable drug-delivery systems. Nature 388, 860–862 (doi:10.1038/42218) doi: 10.1038/42218. [PubMed] [Cross Ref]
76. Huang MH, Huang CY, Lien SP, Siao SY, Chou AH, Chen HW, Liu SJ, Leng CH, Chong P. 2009. Development of multi-phase emulsions based on bioresorbable polymers and oily adjuvant. Pharm. Res. 26, 1856–1862 (doi:10.1007/s11095-009-9898-y) doi: 10.1007/s11095-009-9898-y. [PubMed] [Cross Ref]
77. Andrianov AK, Payne LG. 1998. Polymeric carriers for oral uptake of microparticulates. Adv. Drug Deliv. Rev. 34, 155–170 (doi:10.1016/S0169-409X(98)00038-6) doi: 10.1016/S0169-409X(98)00038-6. [PubMed] [Cross Ref]
78. Payne LG, Jenkis SA, Woods AL, Grund EM, Geribo WE, Loebelenz JR, Andrianov AK, Roberts BE. 1998. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine 17, 92–98 (doi:10.1016/S0264-410X(97)00149-7) doi: 10.1016/S0264-410X(97)00149-7. [PubMed] [Cross Ref]
79. Mutwiri G, Benjamin P, Soita H, Townsend H, Yost R, Roberts B, Andrianov AK, Babiuk LA. 2007. Poly[di(sodium carboxylatoethylphenoxy) phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine 25, 1204–1213 (doi:10.1016/j.vaccine.2006.10.011) doi: 10.1016/j.vaccine.2006.10.011. [PubMed] [Cross Ref]
80. Mutwiri G, Benjamin P, Soita H, Babiuk LA. 2008. Co-administration of polyphosphazenes β with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with hepatitis B virus surface antigen. Vaccine 26, 2680–2688 (doi:10.1016/j.vaccine.2008.03.031) doi: 10.1016/j.vaccine.2008.03.031. [PubMed] [Cross Ref]
81. Shim DH, Ko HJ, Volker G, Potter AA, Mutwiri G, Babiuk LA, Kweon MN. 2010. Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens. Vaccine 28, 2311–2317 (doi:10.1016/j.vaccine.2009.12.069) doi: 10.1016/j.vaccine.2009.12.069. [PubMed] [Cross Ref]
82. Andrianov AK, DeCollibus DP, Gillis HA, Kha HH, Marin A, Prausnitz MR, Babiuk LA, Townsend H, Mutwiri G. 2009. Poly[di(carboxylatophenoxy) phosphazene] is a potent adjuvant for intradermal immunization. Proc. Natl Acad. Sci. USA 106, 18 936–18 941 (doi:10.1073/pnas.0908842106) doi: 10.1073/pnas.0908842106. [PubMed] [Cross Ref]
83. De-Geest BG, Sanders NN, Sukhorukov GB, Demeester J, De-Smedt SC. 2007. Release mechanisms for polyelectrolyte capsules. Chem. Soc. Rev. 36, 636–649 (doi:10.1039/b600460c) doi: 10.1039/b600460c. [PubMed] [Cross Ref]
84. Sexton A, Whitney PG, Chong SF, Zelikin AN, Johnston APR, De-Rose R, Brooks AG, Caruso F, Kent SJ. 2009. A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules. ACS Nano 3, 3391–3400 (doi:10.1021/nn900715g) doi: 10.1021/nn900715g. [PubMed] [Cross Ref]
85. De-Koker S, Naessens T, De-Geest BG, Bogaert P, Demeester J, De-Smedt S, Grooten J. 2010. Biodegradable polyelectrolyte microcapsules: antigen delivery tools with Th17 skewing activity after pulmonary delivery. J. Immunol. 184, 203–211 (doi:10.4049/jimmunol.0803591) doi: 10.4049/jimmunol.0803591. [PubMed] [Cross Ref]
86. Yu AM, Wang YJ, Barlow E, Caruso F. 2005. Mesoporous silica particles as templates for preparing enzyme-loaded biocompatible microcapsules. Adv. Mater. 17, 1737–1741 (doi:10.1002/adma.200402045) doi: 10.1002/adma.200402045. [Cross Ref]
87. Decher G. 1997. Fuzzy nanoassemblies: toward layered polymeric multicomposites. Science 277, 1232–1237 (doi:10.1126/science.277.5330.1232) doi: 10.1126/science.277.5330.1232. [Cross Ref]
88. Khaitov RM. 1990. Molecular bases for the construction of artificial immunogens. J. Biomed. Sci. 1, 122–126. [PubMed]
89. Nandakumar KS, Muthukkaruppan VR. 1999. Influence of immunopotentiators on the antiporin immunoglobulin G subclass: distribution and protective immunity against murine salmonellosis. Scand. J. Immunol. 50, 188–194 (doi:10.1046/j.1365-3083.1999.00576.x) doi: 10.1046/j.1365-3083.1999.00576.x. [PubMed] [Cross Ref]
90. Petrov RV, Khaitov RM, Ataullakhanov RI. 1987. Artificial antigens and vaccines based on non-natural polyelectrolytes. Sov. Med. Rev. D Immunol. Rev. 1, 241–443.
91. Mallapragada SK, Narasimhan B. 2008. Immunomodulatory biomaterials. Int. J. Pharm. 364, 265–271 (doi:10.1016/j.ijpharm.2008.06.030) doi: 10.1016/j.ijpharm.2008.06.030. [PubMed] [Cross Ref]
92. Torres MP, Determan AS, Anderson GL, Mallapragada SK, Narasimhan B. 2007. Amphiphilic polyanhydrides for protein stabilization and release. Biomaterials 28, 108–116 (doi:10.1016/j.biomaterials.2006.08.047) doi: 10.1016/j.biomaterials.2006.08.047. [PubMed] [Cross Ref]
93. Adler AF, Petersen LK, Wilson JH, Torres MP, Thorstenson JB, Gardner SW, Mallapragada SK, Wannemuehler MJ, Narasimhan B. 2009. High throughput cell-based screening of biodegradable polyanhydride libraries. Comb. Chem. High Throughput Screen 12, 634–645 (doi:10.2174/138620709788923764) doi: 10.2174/138620709788923764. [PubMed] [Cross Ref]
94. Shen EE, Kipper MJ, Dziadul B, Lim MK, Narasimhan B. 2002. Mechanistic relationships between polymer microstructure and release kinetics in bioerodible polyanhydrides. J. Control. Release 82, 115–125 (doi:10.1016/S0168-3659(02)00125-6) doi: 10.1016/S0168-3659(02)00125-6. [PubMed] [Cross Ref]
95. Kipper MJ, Wilson JH, Wannemuehler MJ, Narasimhan B. 2006. Single dose vaccine based on biodegradable polyanhydride microspheres can modulate immune response mechanism. J. Biomed. Mater. Res. A 76, 798–810 (doi:10.1002/jbm.a.30545) doi: 10.1002/jbm.a.30545. [PubMed] [Cross Ref]
96. Torres MP, Wilson-Welder JH, Lopac SK, Phanse Y, Carrillo-Conde B, Ramer-Tait AE, Bellaire BH, Wannemuehler MJ, Narasimhan B. 2011. Polyanhydride microparticles enhance dendritic cell antigen presentation and activation. Acta Biomater. 7, 2857–2864 (doi:10.1016/j.actbio.2011.03.023) doi: 10.1016/j.actbio.2011.03.023. [PubMed] [Cross Ref]
97. Petersen LK, Ramer-Tait AE, Broderick SR, Kong CS, Ulery BD, Rajan K, Wannemuehler MJ, Narasimhan B. 2011. Activation of innate immune responses in a pathogen-mimicking manner by amphiphilic polyanhydride nanoparticle adjuvants. Biomaterials 32, 6815–6822 (doi:10.1016/j.biomaterials.2011.05.063) doi: 10.1016/j.biomaterials.2011.05.063. [PubMed] [Cross Ref]
98. Camacho AI, Costa Martins RD, Tamayo I, de-Souza J, Lasarte JJ, Mansilla C, Esparza I, Irache JM, Gamazo C. 2011. Poly(methyl vinyl ether-co-maleic anhydride) nanoparticles as innate immune system activators. Vaccine 29, 7130–7135 (doi:10.1016/j.vaccine.2011.05.072) doi: 10.1016/j.vaccine.2011.05.072. [PubMed] [Cross Ref]
99. Moghimi SM, Hunter AC. 2000. Poloxamers and poloxamines in nanoparticles engineering and experimental medicine. Trends Biotechnol. 18, 412–420 (doi:10.1016/S0167-7799(00)01485-2) doi: 10.1016/S0167-7799(00)01485-2. [PubMed] [Cross Ref]
100. Howerton DA, Hunter RL, Ziegler HK, Check IJ. 1990. Induction of macrophage Ia expression in vivo by synthetic copolymer L81. J. Immunol. 144, 1578–1584. [PubMed]
101. Robinson SN, Chavez JM, Pisarev VM, Mosley RL, Rosenthal GJ, Blonder JM, Talmadge JE. 2003. Delivery of Flt3 ligand (Flt3L) using a poloxamer-based formulation increases biological activity in mice. Bone Marrow Transplant. 31, 361–369 (doi:10.1038/sj.bmt.1703816) doi: 10.1038/sj.bmt.1703816. [PubMed] [Cross Ref]
102. Hunter RL, Bennett B. 1984. The adjuvant activity of non-ionic block polymer surfactants. II. Antibody formation and inflammation to the structure of triblocks and octablock copolymers. J. Immunol. 133, 3167–3175. [PubMed]
103. Hunter RL, Bennett B. 1986. The adjuvant activity of non-ionic block polymer surfactants. Ill. Characterization of selected biologically active surfaces. Scand. J. Immunol. 23, 287–300 (doi:10.1111/j.1365-3083.1986.tb01970.x) doi: 10.1111/j.1365-3083.1986.tb01970.x. [PubMed] [Cross Ref]
104. Discher DE, Ahmed F. 2006. Polymerasomes. Annu. Rev. Biomed. Eng. 8, 323–341 (doi:10.1146/annurev.bioeng.8.061505.095838) doi: 10.1146/annurev.bioeng.8.061505.095838. [PubMed] [Cross Ref]
105. Holowka EP, Sun VZ, Kamei DT, Deming TJ. 2007. Polyarginine segments in block copolypeptides drive both vesicular assembly and intracellular delivery. Nat. Mater. 6, 52–57 (doi:10.1038/nmat1794) doi: 10.1038/nmat1794. [PubMed] [Cross Ref]
106. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. 2006. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control. Release 112, 26–34 (doi:10.1016/j.jconrel.2006.01.006) doi: 10.1016/j.jconrel.2006.01.006. [PubMed] [Cross Ref]
107. Rehor A, Hubbell JA, Tirelli N. 2005. Oxidation-sensitive polymeric nanoparticles. Langmuir 21, 411–417 (doi:10.1021/la0478043) doi: 10.1021/la0478043. [PubMed] [Cross Ref]
108. Stieneker F, Kersten G, van Bloois L, Crommelin DJ, Hem SL, Löwer J, Kreuter J. 1995. Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations. Vaccine 13, 45–53 (doi:10.1016/0264-410X(95)80010-B) doi: 10.1016/0264-410X(95)80010-B. [PubMed] [Cross Ref]
109. Kreuter J, Mauler R, Gruschkau H, Speiser PP. 1976. The use of new polymethylmethacrylate adjuvants for split influenza vaccines. Exp. Cell Biol. 44, 12–19. [PubMed]
110. Kreuter J, Liehl E. 1978. Protection induced by inactivated influenza virus vaccines with polymethylmethacrylate adjuvants. Med. Microbiol. Immunol. 165, 111–117 (doi:10.1007/BF02122746) doi: 10.1007/BF02122746. [PubMed] [Cross Ref]
111. Ji W, Panus D, Palumbo RN, Tang R, Wang C. 2011. Poly(2-aminoethyl methacrylate) with well defined chain length for DNA vaccine delivery to dendritic cells. Biomacromolecules 12, 4373–4385 (doi:10.1021/bm201360v) doi: 10.1021/bm201360v. [PMC free article] [PubMed] [Cross Ref]
112. Hu Y, Litwin T, Nagaraja AR, Kwong B, Katz J, Watson N, Irvine DJ. 2007. Cytosolic delivery of membrane-impermeable molecules in dendritic cells using pH-responsive core-shell nanoparticles. Nano Lett. 7, 3056–3064 (doi:10.1021/nl071542i) doi: 10.1021/nl071542i. [PubMed] [Cross Ref]
113. Hu Y, Atukorale PU, Lu JJ, Moon JJ, Um SH, Cho EC, Wang Y, Chen J, Irvine DJ. 2009. Cytosolic delivery mediated via electrostatic surface binding of protein, virus, or siRNA cargos to pH-responsive core-shell gel particles. Biomacromolecules 10, 756–765 (doi:10.1021/bm801199z) doi: 10.1021/bm801199z. [PMC free article] [PubMed] [Cross Ref]
114. Beaudette TT, et al. 2009. In vivo studies on the effect of co-encapsulation of CpG DNA and antigen in aciddegradable microparticle vaccines. Mol. Pharmacol. 6, 1160–1169 (doi:10.1021/mp900038e) doi: 10.1021/mp900038e. [PMC free article] [PubMed] [Cross Ref]
115. Jong S, et al. 2007. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN. Cancer Immunol. Immunother. 56, 1251–1264 (doi:10.1007/s00262-006-0276-x) doi: 10.1007/s00262-006-0276-x. [PubMed] [Cross Ref]
116. Prasad S, Cody V, Saucier-Sawyer JK, Saltzman WM, Sasaki CT, Edelson RL, Birchall MA, Hanlon DJ. 2011. Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy. Nanomedicine 7, 1–10. [PMC free article] [PubMed]
117. Slutter B, et al. 2010. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice. against the encapsulated antigen. Vaccine 28, 6282–6291. [PubMed]
118. Brunner R, Jensen-Jarolim E, Pali-Scholl I. 2010. The ABC of clinical and experimental adjuvants: a brief overview. Immunol. Lett. 128, 29–35 (doi:10.1016/j.imlet.2009.10.005) doi: 10.1016/j.imlet.2009.10.005. [PMC free article] [PubMed] [Cross Ref]
119. Diwan M, Elamanchili P, Cao M, Samuel J. 2004. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery. Curr. Drug Delivery 1, 405–412 (doi:10.2174/1567201043334597) doi: 10.2174/1567201043334597. [PubMed] [Cross Ref]
120. Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, Cresswell P, Edelson RL, Saltzman WM, Hanlon DJ. 2006. Enhanced and prolonged crosspresentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 117, 78–88 (doi:10.1111/j.1365-2567.2005.02268.x) doi: 10.1111/j.1365-2567.2005.02268.x. [PubMed] [Cross Ref]
121. Kelly C, Jefferies C, Cryan SA. 2011. Targeted liposomal drug delivery to monocytes and macrophages. J. Drug Delivery 2011, 1–11 (doi:10.1155/2011/727241) doi: 10.1155/2011/727241. [PMC free article] [PubMed] [Cross Ref]
122. Jain RA. 2000. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21, 2475–2490 (doi:10.1016/S0142-9612(00)00115-0) doi: 10.1016/S0142-9612(00)00115-0. [PubMed] [Cross Ref]
123. Baras B, Benoit MA, Dupre L, Poulain-Godefroy O, Schacht AM, Capron A, Gillard J, Riveau G. 1999. Single-dose mucosal immunization with biodegradable microparticles containing a Schistosoma mansoni antigen. Infect. Immun. 67, 2643–2648. [PMC free article] [PubMed]
124. Mata E, Igartua M, Patarroyo ME, Pedraz JL, Hernández RM. 2011. Enhancing immunogenicity to PLGA microparticulate systems by incorporation of alginate and RGD-modified alginate. Eur. J. Pharm. Sci. 44, 32–40 (doi:10.1016/j.ejps.2011.05.015) doi: 10.1016/j.ejps.2011.05.015. [PubMed] [Cross Ref]
125. Martínez Gómez JM, Csaba N, Fischer S, Sichelstiel A, Kündig TM, Gander B, Johansen P. 2008. Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis. J. Control. Release 130, 161–167 (doi:10.1016/j.jconrel.2008.06.003) doi: 10.1016/j.jconrel.2008.06.003. [PubMed] [Cross Ref]
126. Mueller M, Schlosser E, Gander B, Groettrup M. 2011. Tumor eradication by immunotherapy with biodegradable PLGA microspheres—an alternative to incomplete Freund's adjuvant. Int. J. Cancer 129, 407–416 (doi:10.1002/ijc.25914) doi: 10.1002/ijc.25914. [PubMed] [Cross Ref]
127. Temmerman MLD, Rejman J, Vandenbroucke RE, Koker SD, Libert C, Grooten J, Demeester J, Gander B, Smedt SCD. 2012. Polyelectrolyte LbL microcapsules versus PLGA microparticles for immunization with a protein antigen. J. Control. Release 158, 233–239 (doi:10.1016/j.jconrel.2011.10.029) doi: 10.1016/j.jconrel.2011.10.029. [PubMed] [Cross Ref]
128. Singh J, Pandit S, Bramwell VW, Alpar HO. 2006. Diphtheria toxoid loaded poly-(ε-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods 38, 96–105 (doi:10.1016/j.ymeth.2005.11.003) doi: 10.1016/j.ymeth.2005.11.003. [PubMed] [Cross Ref]
129. Palumbo RN, Zhong X, Panus D, Han W, Ji W, Wang C. 2012. Transgene expression and local tissue distribution of naked and polymer-condensed plasmid DNA after intradermal administration in mice. J. Control. Release 159, 232–239 (doi:10.1016/j.jconrel.2012.01.012) doi: 10.1016/j.jconrel.2012.01.012. [PMC free article] [PubMed] [Cross Ref]
130. Makela O, Seppala IJ, Vaara M. 1983. LPS greatly enhances the antibody response to hapten-polysaccharide conjugates, but not to hapten–protein conjugates. Annu. Rev. Immunol. 134D, 25–36. [PubMed]
131. Ohno N, et al. 1999. Solubilization of yeast cell-wall β-(1/3)-d-glucan by sodium hypochlorite oxidation and dimethyl sulfoxide extraction. Carbohydrate Res. 316, 161–172 (doi:10.1016/S0008-6215(99)00049-X) doi: 10.1016/S0008-6215(99)00049-X. [PubMed] [Cross Ref]
132. Hida S, Miura NN, Adachi Y, Ohno N. 2007. Cell wall β-glucan derived from Candida albicans acts as a trigger for autoimmune arthritis in SKG mice. Biol. Pharm. Bull. 30, 1589–1592 (doi:10.1248/bpb.30.1589) doi: 10.1248/bpb.30.1589. [PubMed] [Cross Ref]
133. Keystone EC, Schorlemmer HU, Pope C, Allison AC. 1977. Zymosan-induced arthritis. Arthritis Rheum. 20, 1396–1401 (doi:10.1002/art.1780200714) doi: 10.1002/art.1780200714. [PubMed] [Cross Ref]
134. Kelkka T, Hultqvist M, Nandakumar KS, Holmdahl R. 2012. Enhancement of antibody-induced arthritis via toll-like receptor 2 stimulation is regulated by granulocyte reactive oxygen species. Am. J. Pathol. 181, 141–150 (doi:10.1016/j.ajpath.2012.03.031) doi: 10.1016/j.ajpath.2012.03.031. [PubMed] [Cross Ref]
135. Hultqvist M, Nandakumar KS, Björklund U, Holmdahl R. 2010. Rabeximod reduces arthritis severity in mice by decreasing activation of inflammatory cells. Annal. Rheum. Dis. 69, 1527–1532 (doi:10.1136/ard.2009.121178) doi: 10.1136/ard.2009.121178. [PubMed] [Cross Ref]
136. Shenoy M, Christadoss P. 1983. Induction of experimental autoimmune myasthenia gravis with acetylcholine receptors using a non-ionic copolymer as adjuvant. Immunol. Invest. 22, 267–282 (doi:10.3109/08820139309063408) doi: 10.3109/08820139309063408. [PubMed] [Cross Ref]
137. Shakya AK, Kumar A, Nandakumar KS. 2011. Adjuvant properties of a biocompatible thermo-responsive polymer of N-isopropylacrylamide in autoimmunity and arthritis. J. R. Soc. Interface 8, 1748–1759 (doi:10.1098/rsif.2011.0114) doi: 10.1098/rsif.2011.0114. [PMC free article] [PubMed] [Cross Ref]
138. Shakya AK, Kumar A, Klaczkowska D, Hultqvist M, Hagenow K, Holmdahl R, Nandakumar KS. 2011. Collagen type II and a thermo-responsive polymer of N-isopropylacrylamide induce arthritis independent of Toll-like receptors: a strong influence by major histocompatibility complex class II and Ncf1 genes. Am. J. Pathol. 179, 2490–2500 (doi:10.1016/j.ajpath.2011.07.034) doi: 10.1016/j.ajpath.2011.07.034. [PubMed] [Cross Ref]
139. Goldblum RM, Pelley RP, O'Donell AA, Pyron D, Heggers JP. 1992. Antibodies to silicone elastomers and reactions to ventriculoperitoneal shunts. Lancet 340, 510–513 (doi:10.1016/0140-6736(92)91710-P) doi: 10.1016/0140-6736(92)91710-P. [PubMed] [Cross Ref]
140. Bekerecioglu M, Onat AM, Tercan M, Buyukhatipoglu H, Karakok M, Isik D, Bulut O. 2008. The association between silicone implants and both antibodies and autoimmune diseases. Clin. Rheumatol. 27, 147–150 (doi:10.1007/s10067-007-0659-1) doi: 10.1007/s10067-007-0659-1. [PubMed] [Cross Ref]
141. Louis JA, Lambert PH. 1979. Lipopolysaccharides: from immunostimulation to autoimmunity. Immunopathology 2, 215–228.
142. Hida S, Miura NN, Adachi Y, Ohno N. 2005. Effect of Candida albicans cell wall glucan as adjuvant for induction of autoimmune arthritis in mice. J. Autoimmunity 25, 93–101 (doi:10.1016/j.jaut.2005.06.002) doi: 10.1016/j.jaut.2005.06.002. [PubMed] [Cross Ref]
143. Hida S, Nagi-Miura N, Adachi Y, Ohno N. 2006. β-Glucan derived from zymosan acts as an adjuvant for collagen-induced arthritis. Microbiol. Immunol. 50, 453–461. [PubMed]
144. Claman HN. 1963. Tolerance to a protein antigen in adult mice and the effect of non-specific factors. J. Immunol. 91, 833–839. [PubMed]
145. Seppala IJ, Mxkelx O. 1984. Adjuvant effect of bacterial LPS and/or alum precipitation in responses to polysaccharide and protein antigens. Immunology 53, 827–836. [PubMed]
146. Liideritz O, Westphal O, Staub AM, Nikaido H. 1971. Isolation and chemical and immunological characterization of bacterial lipopolysaccharide. In vol. 4 (eds Weinbaum G, Kadis S, Ajl SJ, editors. ), pp. 145 New York, NY: Academic Press.
147. Louis JA, Chiller JM, Weigle WO. 1973. The ability of bacterial lipopolysvccharide to modulate the induction of unresponsiveness to a state of immunity. Cellular parameters. J. Exp. Med. 138, 1481–1495 (doi:10.1084/jem.138.6.1481) doi: 10.1084/jem.138.6.1481. [PMC free article] [PubMed] [Cross Ref]
148. Franzl RE, Mcmaster PD. 1968. The primary immune response in mice. I. The enhancement and suppression of hemolysin production by a bacterial endotoxin. J. Exp. Med. 127, 1087–1107 (doi:10.1084/jem.127.6.1087) doi: 10.1084/jem.127.6.1087. [PMC free article] [PubMed] [Cross Ref]
149. Adachi Y, Suzuki Y, Ohno N, Yadomae T. 1998. Adjuvant effect of grifolan on antibody production in mice. Biol. Pharm. Bull. 21, 974–977 (doi:10.1248/bpb.21.974) doi: 10.1248/bpb.21.974. [PubMed] [Cross Ref]
150. Kurihara K, Shingo Y, Miura NN, Horie S, Usui Y, Adachi Y, Yadomae T, Ohno N. 2003. Effect of CAWS, a mannoprotein-beta-glucan complex of Candida albicans, on leukocyte, endothelial cell, and platelet functions in vitro. Biol. Pharm. Bull. 26, 233–240 (doi:10.1248/bpb.26.233) doi: 10.1248/bpb.26.233. [PubMed] [Cross Ref]
151. Ohno N. 2003. Chemistry and biology of angiitis inducer, Candida albicans water-soluble mannoprotein-beta-glucan complex (CAWS). Microbiol. Immunol. 47, 479–490. [PubMed]
152. Tokunaka K, Ohno N, Adachi Y, Tanaka S, Tamura H, Yadomae T. 2000. Immunopharmacological and immunotoxicological activities of a watersoluble (1/3)-beta-d-glucan, CSBG from Candida spp. Int. J. Immunopharmacol. 22, 383–394 (doi:10.1016/S0192-0561(99)00093-4) doi: 10.1016/S0192-0561(99)00093-4. [PubMed] [Cross Ref]
153. Sato M, et al. 2003. Direct binding of Toll-like receptor 2 to zymosan, and zymosan induced NF-κB activation and TNF-α secretion are down-regulated by lung collectin surfactant protein A. J. Immunol. 171, 417–425. [PubMed]
154. Dillon S, et al. 2006. Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J. Clin. Invest. 116, 916–928 (doi:10.1172/JCI27203) doi: 10.1172/JCI27203. [PMC free article] [PubMed] [Cross Ref]
155. Ibusuki S, Matsuda T, Iwamoto Y. 2003. Tissue engineered cartilage using thermo-responsive gelatin as an in situ forming and moldable scaffold with chondrocytes: in vitro and in vivo performances. Arthritis Res. Ther. 5, 61. (doi:10.1186/ar862) doi: 10.1186/ar862. [Cross Ref]
156. Agmon-Levin N, Hughes GRV, Shoenfeld Y. 2012. The spectrum of ASIA: ‘autoimmune (auto-inflammatory) syndrome induced by adjuvants. Lupus 21, 118–120 (doi:10.1177/0961203311429316) doi: 10.1177/0961203311429316. [PubMed] [Cross Ref]
157. Schaefer CJ, Wooley PH. 1999. The influence of silicone implantation on murine lupus in MRL lpr/lpr mice. J. Rheumatol. 26, 2215–2221. [PubMed]
158. Zandman-Goddard G, Blank M, Ehrenfeld M, Gilburd B, Peter J, Shoenfeld Y. 1999. A comparison of auto-antibody production in asymptomatic and symptomatic women with silicone breast implants. J. Rheumatol. 26, 73–77. [PubMed]
159. Nancy AL, Shoenfeld Y. 2008. Chronic fatigue syndrome with autoantibodies–the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun. Rev. 8, 52–55 (doi:10.1016/j.autrev.2008.07.026) doi: 10.1016/j.autrev.2008.07.026. [PubMed] [Cross Ref]
160. Kumagai Y, Shiokawa Y, Medsger TAJ, Rodnan GP. 1984. Clinical spectrum of connective tissue disease after cosmetic surgery. Observations on eighteen patients and a review of the Japanese literature. Arthritis Rheum. 27, 1–12 (doi:10.1002/art.1780270101) doi: 10.1002/art.1780270101. [PubMed] [Cross Ref]
161. Chizzolini C. 2007. Update on pathophysiology of scleroderma with special reference to immunoinflammatory events. Annal. Med. 39, 42–53 (doi:10.1080/07853890601098152) doi: 10.1080/07853890601098152. [PubMed] [Cross Ref]
Articles from Journal of the Royal Society Interface are provided here courtesy of
The Royal Society